德国慢性肾脏病研究:自我报告用药与尿液药物代谢物的关联
该研究在德国慢性肾脏病(GCKD)队列的4885名患者中,比较了自我报告的158种物质和41个药物组的使用情况与基于非靶向质谱法测定的尿液药物代谢物水平。结果显示,对于36种以原型药物测定的物质,准确率中位数为98.5%;对于66对物质与相关代谢物,特异性中位数为99.2%,敏感性中位数为71.7%。常用降压和心血管药物显示高敏感性和特异性,而自我报告镇痛药使用率低于3%,但代谢物水平提示使用率更高(对乙酰氨基酚10%-26%,布洛芬10%-18%)。
要点
- 尿液药物代谢物检测可验证CKD患者用药依从性,常用心血管药物敏感性和特异性高。
- 自我报告的非处方镇痛药使用率显著低于代谢物提示的实际使用率。
- 药物代谢组学有助于发现CKD患者未报告的用药情况。
核心结论
- 尿液药物代谢物与自我报告用药的关联支持药物代谢组学用于评估CKD患者用药依从性和处方模式。
- 代谢物水平提示非处方镇痛药存在低报现象。
研究设计与样本
- 德国慢性肾脏病(GCKD)研究队列,纳入4885名CKD患者。
- 自我报告158种物质和41个药物组的使用,采用非靶向质谱法量化尿液代谢物。
- 计算特异性、敏感性和准确性,并用多变量回归模型评估关联和处方模式。
主要发现
- 36种以原型药物测定的物质,准确率中位数98.5%(范围61.1%-100%)。
- 66对物质与相关药物代谢物,特异性中位数99.2%(范围84.0%-100%),敏感性中位数71.7%(范围1.2%-100%)。
- 常用降压和心血管药物(血管紧张素II受体阻滞剂、钙通道阻滞剂、美托洛尔)显示高敏感性和特异性。
- 自我报告对乙酰氨基酚使用率<3%,代谢物提示10%-26%;布洛芬自我报告<3%,代谢物提示10%-18%。
临床怎么用
- 临床可考虑用尿液药物代谢物检测辅助评估CKD患者用药依从性,尤其是心血管药物。
- 对非处方镇痛药的使用应警惕患者低报,必要时结合代谢物检测核实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy is common among patients with CKD, but little is known about the urinary excretion of many drugs and their metabolites among patients with CKD. METHODS: To evaluate self-reported medication use in relation to urine drug metabolite levels in a large cohort of patients with CKD, the German Chronic Kidney Disease study, we ascertained self-reported use of 158 substances and 41 medication groups, and coded active ingredients according to the Anatomical Therapeutic Chemical Classification System. We used a nontargeted mass spectrometry-based approach to quantify metabolites in urine; calculated specificity, sensitivity, and accuracy of medication use and corresponding metabolite measurements; and used multivariable regression models to evaluate associations and prescription patterns. RESULTS: Among 4885 participants, there were 108 medication-drug metabolite pairs on the basis of reported medication use and 78 drug metabolites. Accuracy was excellent for measurements of 36 individual substances in which the unchanged drug was measured in urine (median, 98.5%; range, 61.1%-100%). For 66 pairs of substances and their related drug metabolites, median measurement-based specificity and sensitivity were 99.2% (range, 84.0%-100%) and 71.7% (range, 1.2%-100%), respectively. Commonly prescribed medications for hypertension and cardiovascular risk reduction-including angiotensin II receptor blockers, calcium channel blockers, and metoprolol-showed high sensitivity and specificity. Although self-reported use of prescribed analgesics (acetaminophen, ibuprofen) was <3% each, drug metabolite levels indicated higher usage (acetaminophen, 10%-26%; ibuprofen, 10%-18%). CONCLUSIONS: This comprehensive screen of associations between urine drug metabolite levels and self-reported medication use supports the use of pharmacometabolomics to assess medication adherence and prescription patterns in persons with CKD, and indicates under-reported use of medications available over the counter, such as analgesics.
引用
- Kotsis F, Schultheiss UT, Wuttke M, et al. Self-Reported Medication Use and Urinary Drug Metabolites in the German Chronic Kidney Disease (GCKD) Study. J Am Soc Nephrol. 2021. PMID: 34140400. doi:10.1681/ASN.2021010063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。